Fig. 7From: Decreased efficacy of drugs targeting the vascular endothelial growth factor pathway by the epigenetic silencing of FLT1 in renal cancer cells VEGF, FLT1, and KDR methylation in responder and nonresponder patients with renal cancer receiving sunitinib. An analysis of VEGF, FLT1, and KDR methylation statuses is shown for responders and nonresponders. NR nonresponder, R responder, * p < 0.05Back to article page